Clinical Trial Search

Primary: Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16 — 80.1; 79.0 percentage of participants

Primary: Number of Participants With Adverse Events — 12; 1; 4 Participants

Primary: Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score — 0.2 units on a scale

Primary: Number of Participants Who Self-report 7-day Point Prevalence Smoking Abstinence at 6-month Follow-up. — 2; 8 Participants

Primary: Change in HbA1c (%) (Glycosylated Haemoglobin) — -1.11; -1.13 Percentage (%) of HbA1c — p=0.8426

Primary: Change From Baseline Brain Activation in the Ventrolateral Prefrontal Cortex (VLPFC) Based on Change From Baseline to Week 6 in fMRI Blood Oxygen-level Dependent (BOLD)…

Primary: Change From Baseline in A1C at Week 26 (Excluding Rescue Approach) — -0.03; -0.73; -0.91 Percent A1C — p=<0.001

Primary: Overall Disease-Free Survival — 42.8; 43.1 Month — p=0.541

Primary: Adverse Events Possibly or Probably Related to the Investigational Product — 2 Adverse Events

Primary: Number of Participants With Hypersensitivity Adverse Reaction — 111; 119 Participants

Primary: Degree of Hemorrhage Control by Treatment Regimen — 53; 116; 105; 74 Bleeding Episodes

Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against the Flu A/California/7/2009 (H1N1) Vaccine Strain — 5.7; 5.2; 9.9; 192.6…

Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 22.7; 43.4; 72.4 percentage of participants — p=< 0.001

Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 37.0; 57.1; 50.8; 75.9 percentage of participants

Primary: Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment — -0.94; -0.12; -0.91; -0.33 Percentage (%) — p=<0.0001